China I-IIIA NSCLC real world research project started

May 26, 2019 / AP / -- China's I-IIIA NSCLC (non-small cell lung cancer) real world research project, CO sponsored by the National Cancer Center and Beijing Cancer Society, was launched yesterday in Shenzhen, China In China, the incidence rate and mortality rate of lung cancer ranks the highest in all cancers in China Among them, non-small cell lung cancer accounted for 80% of all lung cancer cases [1] The 5-year survival rate of lung cancer is low, 70% of the patients are in the late stage when they are diagnosed, and they miss the opportunity of operation Systemic chemotherapy has been the main treatment choice for these patients At the beginning of the 21st century, the emergence of molecular targeted drugs has made significant clinical progress in the treatment of advanced non-small cell lung cancer Subsequently, tumor immunotherapy is considered to be one of the most successful methods in the field of cancer treatment in recent years However, despite several times of cross era progress in the field of lung cancer treatment in the past decade, the death rate of lung cancer remains high In addition to constantly promoting new treatment programs, it is urgent to understand the impact of treatment programs on patients in the real world, and summarize how to adjust treatment strategies for different patients in the real world, so as to develop more suitable treatment guidelines for Chinese patients Compared with other cancer species, the field of lung cancer treatment has made rapid progress in the past decade With the support of national policies, the speed of new drugs entering China has also become significantly faster China has almost the same treatment guidelines and advanced drugs as other countries However, the five-year survival rate of lung cancer in China is lower than that in Japan, South Korea and the United States Therefore, it is imperative to study the real world Through the findings of real world research, we hope to provide guidance and suggestions for improving the survival rate of lung cancer patients The project is jointly sponsored by the National Cancer Center and Beijing Society of oncology It brings together provincial cancer hospitals across the country to collect treatment data of patients under different economic conditions, different living environments and different diagnosis and treatment concepts The project plans to collect 10000 patients, follow-up for 3 years, a total of 30 hospitals to join, supported by saisheng Pharmaceutical (China) Co., Ltd The main objective is to observe the effect of different treatment schemes on the survival of NSCLC patients in stage I-IIIA in the real world At the same time, the project will also observe the compliance of patients' diagnosis and treatment plans to the guidelines in the real world, so as to provide more reliable decision-making basis for clinical practice Source: Non-Small Cell Lung Cancer [1] NCCN Guidelines Version 6.2018